U.S. markets closed

Jupiter Wellness, Inc. (JUPW)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.0900+0.1600 (+8.29%)
At close: 4:00PM EDT
2.0900 0.00 (0.00%)
After hours: 06:20PM EDT
Sign in to post a message.
  • R
    In at $2.02
  • J
    Jose V
    News Release

    Jupiter Wellness Announces Multi-Year Distribution Agreement with Rigour International for Expansion in Asia
  • b
    Any body here..
  • C
    What is the redemption info for the warrants?
  • s
    Buying this dip
  • D
    Remember company has five employees. Not too promising.
  • J
    Joe Ward
    Anything negative is a short anything positive a bag holder. Normal
  • M
    so they buying justCBD
    that's a game changer if true
  • J
    Jose V
    New Press Release

    JUPITER, FL / July 13, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), today announced a head-to-head trial comparing JW-100 lotion with Eucrisa crisaborole ointment 2% for the treatment of patients with mild to moderate eczema (Atopic Dermatitis). Eucrisa is an FDA-approved topical non-steroidal lotion containing crisaborole approved for the treatment of mild to moderate eczema. JW-100 is a novel non-steroidal topical lotion containing cannabidiol (cbd) and Aspertame for the treatment of mild to moderate eczema.

    The head-to-head clinical trial which will evaluate superiority between JW-100 and Eucrisa in adult patients with mild-to-moderate eczema will be performed in collaboration with Applied Biology who has developed the protocols and will co-ordinate the multi-center trial. The Phase III multi-center trial will be a double-blinded placebo controlled trial.
  • V
    the Bullish Report on AMC Entertainment

  • W
    JUPW pretty clear this sell off is overdone

    Raised $$ will be reinvested, Rigour will bring in millions in revenue.

    Nice time to accumulate more
  • J
    Jose V
    News Release

    JUPITER, FL / June 22, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), today announced the publication of clinical study results to investigate the safety and efficacy of JW-100 its proprietary lotion formulation for the treatment of atopic dermatitis (eczema).

    J Cosmet Dermatol 2021 May 31: Online ahead of print. The peer-reviewed publication reports on a double-blinded placebo-controlled study randomizing patients to one of three treatment groups: JW-100 (CBD plus Aspartame), CBD only, or placebo topical formulations. The Investigator’s Static Global Assessment (ISGA) score was used to document any changes in AD resulting from the applied interventions at 14 days.

    Fifty-seven patients completed the trial and were included in the final analysis. The JW-100 cohorts demonstrated statistically significant ISGA score reduction (p = 0.042). 50% of patients in the JW-100 group achieved ISGA score of clear or almost clear (0 or 1) with at least a 2-grade improvement from baseline after treatment (p = 0.028). Only 20% and 15% of patients in the CBD only and placebo groups reported ISGA score of clear or almost clear (0 or 1). JW-100, a novel topical formulation containing CBD and aspartame, was demonstrated to produce statistically significant improvements in AD following 14 days of topical application.

    The publication is authored by an international group of leading dermatology researchers and clinicians who conducted the studies. The studies were coordinated by Dr. Andy Goren, Chief Medical Officer, Applied Biology Inc. (Irvine, CA). In coordination with Dr. Goren, we have commenced a drug development program of JW-100 for the treatment of atopic dermatitis. Initial filings with the FDA are expected in Q3 of 2021.

    Dr Glynn Wilson, Chief Scientific Officer of Jupiter Wellness commented “Peer-reviewed publication of data from controlled clinical trials conducted by leading clinicians is central to our overall strategy of developing novel medicinal products that have demonstrated safety and efficacy and ultimately receive regulatory approval”.

    Brian John, CEO of Jupiter Wellness added “We are excited by these initial results and the potential for JW-100 to provide a solution superior to existing prescription drugs. The early clinical data shows JW-100’s potential to disrupt the billion-dollar market for the treatment of eczema”.
  • T
    10 dollars soon
  • D
    This name could very well catch on. In the afternoon, when the Reddit crowd wakes up to this, it could catch on fire... Also, there is, in fact, a good reason for it to spike...
  • A
    Full-time employees: 5 lol
  • H
    10+ this week
  • T
    $TKAT conversation
    Check $JUPW guys
    CBD company with great earnings, very low float, multiples websites, selling to big partners, having clinical trials on herpes, eczema with cbd products
  • J
    How is everyone today ?
  • m
    Hows everyone feeling today
  • J
    Jose V
    Today's press release

    JUPITER, FL / ACCESSWIRE / April 16, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a leading developer of cannabidiol (CBD) based medical therapeutics and wellness products, today announced it has appointed Dr. Glynn Wilson as Chief Science Officer, Rich Miller as Chief Compliance Officer, and Ryan Allison as Chief Operating Officer. Over the past quarters, Jupiter has grown its CBD-based consumer wellness business to include 40 products across seven brands in six categories, while also advancing its clinical pipeline with three indications in Phase 1 equivalent studies and one indication ready for an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) based on a successful Phase 1 equivalent which met its primary endpoint.

    Dr. Glynn Wilson, who continues to serve as Chairman of the Board and was formerly Head of R&D at Jupiter, will now serve as Chief Science Officer overseeing Jupiter’s pipeline of clinical indications including eczema. Should JW-100 continue to show similar efficacy in advanced stage trials, Jupiter’s lead product candidate would address a $10 billion global market, in which a competing product is projected to reach $2 billion in annual sales. Dr. Wilson will guide the development strategy and clinical design for Jupiter’s CBD-based topical product candidates for indications including skin cancer, burns, and herpes cold sores, all of which are currently in Phase 1 equivalent human trials. Dr. Wilson was formerly Head of Drug Delivery at SmithKline Beecham and was Founder, CEO and Chairman of TapImmune, a developer of cancer vaccines.

    Rich Miller continues to serve as a Director for Jupiter and now moves into the newly created position of Chief Compliance Officer overseeing regulatory affairs for securities, CBD-based products, Jupiter’s subsidiaries, manufacturing, and international trade. As Jupiter expands through both organic growth and acquisition, Mr. Miller serves a critical role in assuring the Company defines best practices in innovation as a leader in its industry segments.

    Ryan Allison, formerly Vice President of Business Development, moves into the position of Chief Operating Officer overseeing growth as Jupiter capitalizes on unprecedented opportunities in the CBD pharma and wellness space. Mr. Allison is a strong leader who has been at the forefront of building high-performance, data-driven organizations and business infrastructure throughout his career across many industries including healthcare and the federal government. Earlier in his career Mr. Allison served at VMware where he was an early member of the cloud computing team and an instrumental player in securing a foothold in the infant cloud landscape, a market segment VMware continues to lead in today.

    "I am confident these new adjustments to our leadership team have Jupiter Wellness prepared for the explosive growth we are expecting to see in the CBD market. I am thrilled that we have access to such high caliber talent across our team as we step into our second quarter.," stated Brian John, CEO of Jupiter Wellness.